MA32064B1 - Nouvelles pyridinones et pyridazinones - Google Patents

Nouvelles pyridinones et pyridazinones

Info

Publication number
MA32064B1
MA32064B1 MA33066A MA33066A MA32064B1 MA 32064 B1 MA32064 B1 MA 32064B1 MA 33066 A MA33066 A MA 33066A MA 33066 A MA33066 A MA 33066A MA 32064 B1 MA32064 B1 MA 32064B1
Authority
MA
Morocco
Prior art keywords
phenyl
iii
diseases associated
pyridinones
pyridazinones
Prior art date
Application number
MA33066A
Other languages
Arabic (ar)
English (en)
Inventor
Nolan James Dewdney
Joshua Kennedy-Smith
Rama K Kondru
Bradley E Loe
Yan Lou
Joel Mcintosh
Timothy D Owens
Michael Soth
Zachary Kevin Sweeney
Joshua Paul Gergely Taygerly
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA32064B1 publication Critical patent/MA32064B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Cette invention porte sur des dérivés de 5-phényl-1h-pyridin-2-one et de 6-phényl-2h-pyridazin-3-one selon les formules génériques i-iii : dans lesquelles les variables r, x, y1, y2, y3, y4, n et m sont définies comme décrit dans la description, les dérivés inhibant btk. Les composés décrits dans la description sont utiles pour moduler l'activité de btk et traiter des maladies associées à une activité de btk excessive. Les composés sont encore utiles pour traiter des maladies inflammatoires et auto-immunes associées à une prolifération aberrante des lymphocytes b telles que la polyarthrite rhumatoïde. L'invention porte également sur des compositions contenant des composés représentés par les formules i-iii et au moins un support, diluent ou excipient.
MA33066A 2008-02-05 2010-08-06 Nouvelles pyridinones et pyridazinones MA32064B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2620408P 2008-02-05 2008-02-05
US12251008P 2008-12-15 2008-12-15
PCT/EP2009/050875 WO2009098144A1 (fr) 2008-02-05 2009-01-27 Nouvelles pyridinones et pyridazinones

Publications (1)

Publication Number Publication Date
MA32064B1 true MA32064B1 (fr) 2011-02-01

Family

ID=40413736

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33066A MA32064B1 (fr) 2008-02-05 2010-08-06 Nouvelles pyridinones et pyridazinones

Country Status (29)

Country Link
EP (1) EP2242749B1 (fr)
JP (1) JP5259739B2 (fr)
KR (1) KR101308803B1 (fr)
CN (1) CN101932573B (fr)
AR (1) AR070408A1 (fr)
AU (1) AU2009211514B2 (fr)
BR (1) BRPI0907915A2 (fr)
CA (1) CA2710462C (fr)
CL (1) CL2009000229A1 (fr)
CO (1) CO6290767A2 (fr)
CR (1) CR11598A (fr)
CY (1) CY1114114T1 (fr)
DK (1) DK2242749T3 (fr)
EC (1) ECSP10010384A (fr)
ES (1) ES2420846T3 (fr)
HR (1) HRP20130615T1 (fr)
IL (1) IL206357A (fr)
MA (1) MA32064B1 (fr)
MX (1) MX2010008197A (fr)
MY (1) MY158411A (fr)
NZ (1) NZ586916A (fr)
PE (1) PE20091484A1 (fr)
PL (1) PL2242749T3 (fr)
PT (1) PT2242749E (fr)
RU (1) RU2505538C2 (fr)
SI (1) SI2242749T1 (fr)
TW (1) TWI382024B (fr)
WO (1) WO2009098144A1 (fr)
ZA (1) ZA201005539B (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012502374A1 (en) 2008-06-24 2014-11-12 Hoffmann La Roche Novel substituted pyridin-2-ones and pyridazin-3-ones
US8299077B2 (en) * 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
WO2010122038A1 (fr) * 2009-04-24 2010-10-28 F. Hoffmann-La Roche Ag Inhibiteurs de la tyrosine kinase de bruton
NZ598985A (en) 2009-09-04 2013-07-26 Biogen Idec Inc Bruton's tyrosine kinase inhibitors
EP2566869B1 (fr) * 2010-05-07 2016-03-02 Gilead Connecticut, Inc. Composés de pyridone et d'aza-pyridone et leurs procédés d'utilisation
EP2394998A1 (fr) * 2010-05-31 2011-12-14 Almirall, S.A. Dérivés de 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl en tant qu'inhibiteurs de la PDE4
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
AU2012257802A1 (en) * 2011-05-17 2013-10-31 F. Hoffmann-La Roche Ag Inhibitors of Bruton's tyrosine kinase
CA2841801A1 (fr) * 2011-08-17 2013-02-21 F.Hoffmann-La Roche Ag Inhibiteurs de la tyrosine kinase de bruton
UA111756C2 (uk) * 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
US9365566B2 (en) 2012-03-27 2016-06-14 Takeda Pharmaceutical Company Limited Cinnoline derivatives
KR20150000882A (ko) 2012-04-05 2015-01-05 씨에이치디아이 파운데이션, 인코포레이티드 키뉴레닌-3-모노산소첨가효소 억제제들, 약학 조성물들 및 이의 사용 방법
JP6182593B2 (ja) 2012-04-20 2017-08-16 アドヴィーナス セラピューティクス リミテッド 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途
AR091273A1 (es) * 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
WO2014040965A1 (fr) * 2012-09-13 2014-03-20 F. Hoffmann-La Roche Ag Inhibiteurs de la tyrosine kinase de bruton
JP6088063B2 (ja) * 2012-11-16 2017-03-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトン型チロシンキナーゼの阻害剤
MX2015006457A (es) * 2012-11-30 2015-08-14 Hoffmann La Roche Inhibidores de la tirosina cinasa de bruton.
RU2618529C2 (ru) * 2013-03-05 2017-05-04 Ф. Хоффманн-Ля Рош Аг Ингибиторы тирозинкиназы брутона
EP2964642B1 (fr) * 2013-03-05 2017-11-15 F. Hoffmann-La Roche AG Inhibiteurs de la tyrosine kinase de bruton
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
CA2902686C (fr) 2013-04-25 2017-01-24 Beigene, Ltd. Composes heterocycliques fusionnes en tant qu'inhibiteurs de proteine kinase
CN104177338B (zh) * 2013-05-22 2018-04-03 南京勇山生物科技有限公司 一类布鲁顿激酶抑制剂
WO2015000949A1 (fr) * 2013-07-03 2015-01-08 F. Hoffmann-La Roche Ag Composés hétéroaryl pyridone et aza-pyridone amide
CN112552401B (zh) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
WO2015082583A1 (fr) * 2013-12-05 2015-06-11 F. Hoffmann-La Roche Ag Composés de pyridone hétéroarylique et d'aza-pyridone à fonctionnalité électrophile
CN106604742B (zh) 2014-07-03 2019-01-11 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
CN106922146B (zh) * 2014-10-02 2020-05-26 豪夫迈·罗氏有限公司 用于治疗由布鲁顿酪氨酸激酶(btk)介导的疾病的吡唑甲酰胺化合物
US10570118B2 (en) * 2016-01-13 2020-02-25 Boehringer Ingelheim International Gmbh Isoquinolones as BTK inhibitors
DK3436447T3 (da) 2016-03-31 2021-09-13 Takeda Pharmaceuticals Co Isoquinolinyl-triazolon-komplekser
US10864203B2 (en) 2016-07-05 2020-12-15 Beigene, Ltd. Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
JP7214632B2 (ja) 2016-07-21 2023-01-30 バイオジェン エムエー インク． ブルトン型チロシンキナーゼ阻害剤のコハク酸塩形態および組成物
WO2018033853A2 (fr) 2016-08-16 2018-02-22 Beigene, Ltd. Forme cristalline de (s)-7-(1-acryloylpipéridin-4-yl)-2-(4-phénoxyphényle)-4,5,6,7-tétra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, sa préparation et ses utilisations
WO2018033135A1 (fr) 2016-08-19 2018-02-22 Beigene, Ltd. Utilisation d'une combinaison comprenant un inhibiteur de btk pour le traitement de cancers
IL292938A (en) 2016-09-19 2022-07-01 Mei Pharma Inc Combined treatment
US11555038B2 (en) 2017-01-25 2023-01-17 Beigene, Ltd. Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
CN106967073A (zh) * 2017-04-24 2017-07-21 刘双伟 一种治疗类风湿性关节炎的药物
CN106946891B (zh) * 2017-05-08 2018-07-13 宿州市徽腾知识产权咨询有限公司 一种用于治疗类风湿性关节炎的药物
EP3645569A4 (fr) 2017-06-26 2021-03-24 BeiGene, Ltd. Immunothérapie pour carcinome hépatocellulaire
US11377449B2 (en) 2017-08-12 2022-07-05 Beigene, Ltd. BTK inhibitors with improved dual selectivity
WO2019108795A1 (fr) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Traitement de lymphomes à cellules b indolentes ou agressives au moyen d'une combinaison comprenant des inhibiteurs de btk
MX2021004191A (es) 2018-10-15 2021-05-27 Nurix Therapeutics Inc Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma.
US12582722B2 (en) 2019-02-13 2026-03-24 Nurix Therapeutics, Inc. Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
CA3136348A1 (fr) 2019-04-09 2020-10-15 Nurix Therapeutics, Inc. Composes de piperidine substitues en position 3 pour l'inhibition de cbl-b, et utilisation d'un inhibiteur de cbl-b en combinaison avec un vaccin contre le cancer et/ou un virus o ncolytique
AU2020278592B2 (en) 2019-05-17 2024-10-10 Nurix Therapeutics, Inc. Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof
US20220249491A1 (en) 2019-06-10 2022-08-11 Beigene Switzerland Gmbh Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor
MX2021015675A (es) 2019-06-26 2022-02-03 Nurix Therapeutics Inc Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos.
EP4034140A1 (fr) 2019-09-24 2022-08-03 Nurix Therapeutics, Inc. Inhibiteurs de cbl et compositions destinés à être utilisés dans une thérapie cellulaire adoptive
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
US20230024442A1 (en) * 2019-11-08 2023-01-26 Nurix Therapeutics, Inc. Bifunctional compounds for grading btk via ubiquitin proteosome pathway
WO2021113557A1 (fr) 2019-12-04 2021-06-10 Nurix Therapeutics, Inc. Composés bifonctionnels pour la dégradation de la btk par l'intermédiaire de la voie de l'ubiquitine-protéosome
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
WO2022217123A2 (fr) 2021-04-08 2022-10-13 Nurix Therapeutics, Inc. Polythérapies comprenant des composés inhibiteurs de cbl-b
CA3236073A1 (fr) 2021-10-26 2023-05-04 Robert J. Brown Composes de piperidinylpyrazine-carboxamide pour le traitement et la prevention du cancer et pour la degradation de btk
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3951395B2 (ja) * 1996-12-13 2007-08-01 田辺製薬株式会社 ピリジン誘導体、その製法及びその合成中間体
ATE278674T1 (de) * 1999-03-12 2004-10-15 Boehringer Ingelheim Pharma Heterocyklischer harnstoff und verwandte verbindungen als entzündungshemmende mittel
ES2232306B1 (es) * 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
US8101770B2 (en) * 2004-12-16 2012-01-24 Vertex Pharmaceuticals Incorporated Pyridones useful as inhibitors of kinases
MY140868A (en) * 2004-12-24 2010-01-29 Astrazeneca Ab Amide derivatives
MX2007011041A (es) * 2005-03-10 2008-02-22 Cgi Pharmaceuticals Inc Ciertas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas.
WO2006124731A2 (fr) * 2005-05-12 2006-11-23 Irm Llc Composes et compositions utilise(e)s en tant qu'inhibiteurs de proteines-kinases
WO2007021795A2 (fr) * 2005-08-09 2007-02-22 Irm Llc Composes et compositions utiles comme inhibiteurs de proteines kinases
ATE548363T1 (de) * 2005-08-29 2012-03-15 Vertex Pharma 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen
MX2008014618A (es) * 2006-05-15 2008-11-28 Irm Llc Composiciones y metodos para inhibidores de cinasas del receptor fgf.

Also Published As

Publication number Publication date
SI2242749T1 (sl) 2013-07-31
HK1146826A1 (en) 2011-07-15
PE20091484A1 (es) 2009-10-03
CY1114114T1 (el) 2016-07-27
JP2011511027A (ja) 2011-04-07
CO6290767A2 (es) 2011-06-20
EP2242749B1 (fr) 2013-04-10
CN101932573A (zh) 2010-12-29
CA2710462C (fr) 2015-11-24
IL206357A (en) 2013-12-31
ZA201005539B (en) 2011-04-28
KR101308803B1 (ko) 2013-09-13
PT2242749E (pt) 2013-07-16
PL2242749T3 (pl) 2013-09-30
ECSP10010384A (es) 2010-09-30
CN101932573B (zh) 2014-06-11
IL206357A0 (en) 2010-12-30
WO2009098144A1 (fr) 2009-08-13
ES2420846T3 (es) 2013-08-27
AR070408A1 (es) 2010-04-07
AU2009211514A1 (en) 2009-08-13
RU2505538C2 (ru) 2014-01-27
KR20100093130A (ko) 2010-08-24
AU2009211514B2 (en) 2014-02-20
TW200938538A (en) 2009-09-16
MX2010008197A (es) 2010-08-23
DK2242749T3 (da) 2013-06-17
CR11598A (es) 2010-10-27
MY158411A (en) 2016-10-14
HRP20130615T1 (en) 2013-08-31
JP5259739B2 (ja) 2013-08-07
RU2010136665A (ru) 2012-03-20
NZ586916A (en) 2012-06-29
TWI382024B (zh) 2013-01-11
CL2009000229A1 (es) 2010-06-04
BRPI0907915A2 (pt) 2015-07-28
EP2242749A1 (fr) 2010-10-27
CA2710462A1 (fr) 2009-08-13

Similar Documents

Publication Publication Date Title
MA32064B1 (fr) Nouvelles pyridinones et pyridazinones
MA32487B1 (fr) Nouvelles pyridine-2-ones et pyridazine-3-ones substituees
MA34465B1 (fr) Inhibiteurs de tyrosine kinase de bruton
MA35112B1 (fr) Inhibiteurs de tyrosine kinase de bruton
MA35419B1 (fr) Inhibiteurs de la tyrosine kinase de bruton
MA32655B1 (fr) Composés modulant sélectivement le récepteur cb2
MA29140B1 (fr) Dérivés de quinoléine hétéroaromatiques et leur utilisation comme inhibiteurs de PDE10
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
MA31763B1 (fr) Inhibiteurs de kinase de type polo
TN2009000112A1 (fr) Derives de sulfonamides servant d'agonistes adrenergiques et d'antagonistes muscariniques
TNSN07248A1 (fr) Derive de pyrrolidyle de composes heteroaromatiques servant d'inhibiteurs de phosphodiesterases
ATE513828T1 (de) Phenyl-ä3-ä3-(1h-pyrrol-2-yl)-ä1,2,4üoxadiazol- - ylüpiperidin-1-ylü-methanon-derivate und verwandte verbindungen als positive allosterische modulatoren metabotroper glutamatrezeptoren
EA017914B8 (ru) 1,4-ДВУЗАМЕЩЕННЫЕ 3-ЦИАНОПИРИДОНОВЫЕ ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЗИТИВНЫХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2
UA87856C2 (ru) Алкильные производные как модуляторы метаботропных рецепторов глутамата
TNSN06358A1 (fr) Methyl-aryl-ou-heteroaryl-amides substitues
TW200634016A (en) Novel thieno-pyridine and thieno-pyrimidine derivatives and their use as positive allosteric modulators of mglur2-receptors
MA28269A1 (fr) Arylpyrazoles substitués servant d'agents parasiticides
MA31766B1 (fr) Composés organiques
MA30289B1 (fr) Dérivés d'amines
DE60231901D1 (de) Dna-synthesepromotoren, mit dna-polymerase assoziierte faktoren und nutzung davon
DE60217186D1 (de) Dpiv-inhibitoren auf glutaminbasis
TW200633982A (en) Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors
ATE423769T1 (de) Fluor- und sulfonylaminohaltige, 3,6- disubstituierte azabicyclo 3.1.0 hexanderivate als muscarinrezeptorantagonisten
UA100126C2 (en) 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1, 4'] bipyridinyl-2'-ones
MA27926A1 (fr) Derives de quinoline et de quinazoline presentant une affinite vis-a-vis des recepteurs du type 5ht1